Restricted Stock Units

 

During the nine months ended September 30, 2020, the Company issued 15,000 restricted stock units (“RSUs”) to each of its three non-management directors as an annual grant for 2020 for service on the Company’s Board of Directors. The RSUs vest in four equal quarterly installments of 3,750 shares of common stock on March 15, 2020, June 15, 2020, September 15, 2020 and December 15, 2020, subject to continued service on the Board of Directors.

 

During the nine months ended September 30, 2019, the Company issued 15,000 RSUs to each of its three non-management directors as an annual grant for 2019 for service on the Company’s Board of Directors. The RSUs vested in four equal quarterly installments of 3,750 shares of common stock on March 15, 2019, June 15, 2019, September 15, 2019 and December 15, 2019.

 

On July 14, 2020, 125,000 RSUs owned by the Company’s Chairman and Chief Executive Officer vested in accordance with his employment agreement (see Note H[1] hereof), and he delivered 50,563 shares of the Company’s common stock to satisfy withholding taxes resulting in 74,437 net shares issued.

   

A summary of restricted stock unit activity for the nine months ended September 30, 2020 is as follows (each restricted stock unit issued by the Company represents the right to receive one share of the Company’s common stock):

 

		Number of Shares				Weighted-Average Grant Date Fair Value
Balance of restricted stock units outstanding at December 31, 2019			340,000			$	2.15
Grants of restricted stock units			45,000				2.30
Vested restricted stock units			(158,750	)			2.10
Balance of unvested restricted stock units at September 30, 2020			226,250			$	2.22

 

Restricted stock unit compensation expense was $85,000 and $154,000 for the three months ended September 30, 2020 and September 30, 2019, respectively. Restricted stock unit compensation expense was $242,000 and $425,000 for the nine months ended September 30, 2020 and September 30, 2019, respectively.

 

The Company has an aggregate of $85,000 of unrecognized restricted stock unit compensation as of September 30, 2020 to be expensed over a weighted average period of 0.57 years.

 

All of the Company’s outstanding (unvested) restricted stock units have dividend equivalent rights. As of September 30, 2020, there was $68,000 accrued for dividend equivalent rights.  As of December 31, 2019, there was $90,000 accrued for dividend equivalent rights.

 

Stock Options

 

There were no stock option grants during the nine months ended September 30, 2020 and September 30, 2019. The following table presents information relating to all stock options outstanding and exercisable at September 30, 2020:

 

Options Outstanding	Weighted Average Exercise  Price	Weighted Average Remaining Life in Years	Options Exercisable
500,000	$1.19	2.09	500,000

 

The Company had no recorded stock-based compensation related to stock option grants for the nine months ended September 30, 2020 and September 30, 2019.

 

The Company had no unrecognized stock-based compensation cost as of September 30, 2020. The aggregate intrinsic value of stock options exercisable at September 30, 2020 was $730,000.

 

During the three months ended September 30, 2020 and September 30, 2019, there were no stock option exercises.

 

During the nine months ended September 30, 2020, stock options to purchase an aggregate of 105,000 shares of the Company’s common stock, at an exercise price of $2.34 per share, were exercised on a net exercise (cashless) basis by three non-management directors of the Company. With respect to the aforementioned stock options, net shares of an aggregate of 4,707 shares were delivered to the non-management directors.

 

During the nine months ended September 30, 2019, stock options to purchase an aggregate of 925,000 shares were exercised by executive officers of the Company and a consultant (750,000 shares at an exercise price of $0.83 per share by the Company’s Chairman and Chief Executive Officer, 50,000 shares at an exercise price of $1.65 per share by each of the Company’s Chief Financial Officer and Executive Vice President and 75,000 shares at an exercise price of $1.65 per share by a consultant). With respect to such options, options to purchase an aggregate of 859,849 shares were exercised on a net exercise (cashless) basis by the Company’s Chairman and Chief Executive Officer (750,000 shares), the Company’s Executive Vice President (34,849 shares) and a consultant (75,000 shares) resulting in 328,111 net shares (after delivery of shares for withholding taxes) issued to the Company’s Chairman and Chief Executive Officer, 27,713 net shares issued to the Company’s Executive Vice President and 28,824 net shares issued to the consultant.

 

During the nine months ended September 30, 2019, stock options to purchase an aggregate of 105,000 shares of the Company’s common stock, at an exercise price of $1.65 per share, were exercised on a net exercise (cashless) basis by three non-management directors of the Company. With respect to the aforementioned stock options, 35,884 net shares were issued to the three non-management directors.